Establishment of DYT5 patient-specific induced pluripotent stem cells with a GCH1 mutation.

Stem Cell Res

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Drug-Discovery Cellular Basis Development Team, RIKEN BioResource Center, Kyoto, Japan. Electronic address:

Published: October 2017

Peripheral blood mononuclear cells (PBMCs) were collected from a clinically diagnosed 20-year-old dystonia patient with a GCH1 mutation (DYT5). Episomal vectors were used to introduce reprogramming factors (OCT3/4, SOX2, KLF4, L-MYC, LIN28, and p53 carboxy-terminal dominant-negative fragment) to the PBMCs. The generated iPSCs expressed pluripotency markers, and were capable of differentiating into derivates of all three germ layers in vitro. The iPSC line also showed a normal karyotype and preserved the GCH1 mutation. This cellular model can provide opportunities to perform pathophysiological studies for aberrant dopamine metabolism-related disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scr.2017.07.029DOI Listing

Publication Analysis

Top Keywords

gch1 mutation
12
establishment dyt5
4
dyt5 patient-specific
4
patient-specific induced
4
induced pluripotent
4
pluripotent stem
4
stem cells
4
cells gch1
4
mutation peripheral
4
peripheral blood
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!